🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06419413
Recruiting Observational

A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population

NCT06419413 · tracked via the Priya Life Science China tracker
Sponsor
AstraZeneca
Phase
Observational
Started
2024-01-08
Last updated
2026-08-18

Condition(s) studied

Asthma

Study summary

A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of Personalised Treatment Strategies in Chinese Population

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age 18 to 75 years of age * acceptable FEV1 (according to ATS and ERS) * compliance with study procedures All Asthma Cohorts * physician diagnosed Asthma greater or equal to 3 months prior to screening visit Exclusion Criteria: * history of alcohol or drug abuse within the past year * pregnant at time of an assessment * has an altered mental status at the time of informed consent * receipt marketed or investigational biologic(s) within 3 months or 5 half-lives prior to visit 1, whichever is longer * history or current upper or lower respiratory infection or symptoms within 2 weeks of baseline assessments * terminal diseases and/or organ failure or participants otherwise considered not appropriate for the study participation * Receipt LTRAs or 5-lipoxygenase (5-LO) inhibitors (eg zileuton and montelukast) within 1 month or 5 half-lives prior to baseline, whichever is longer.

Primary outcome measure(s)

Trial sites (21)

FacilityCityRegionStatus
Research Site Chengdu Sichuan Recruiting
Research Site Beijing China Not Yet Recruiting
Research Site Changsha China Not Yet Recruiting
Research Site Dongguan China Not Yet Recruiting
Research Site Foshan China Not Yet Recruiting
Research Site Guangzhou China Not Yet Recruiting
Research Site Hainan China Not Yet Recruiting
Research Site Hohhot China Not Yet Recruiting
Research Site Huizhou China Not Yet Recruiting
Research Site Kunming China Not Yet Recruiting
Research Site Nanjing China Not Yet Recruiting
Research Site Nanning China Not Yet Recruiting
Research Site Shanghai China Not Yet Recruiting
Research Site Shenyang China Not Yet Recruiting
Research Site Taiyuan China Recruiting
Research Site Wenzhou China Not Yet Recruiting
Research Site Wuhan China Recruiting
Research Site Xi'an China Recruiting
Research Site Xuzhou China Not Yet Recruiting
Research Site Zhanjiang China Not Yet Recruiting
Research Site Zhaoqing China Not Yet Recruiting

More AstraZeneca trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06419413 on ClinicalTrials.gov ↗ ← All trials in China